Journal
AUTOIMMUNITY REVIEWS
Volume 20, Issue 5, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.autrev.2021.102800
Keywords
Innate immunity; Toll-like receptor; Complement; Myasthenia gravis; Thymus
Categories
Funding
- National Natural Science Foundation of China [81870988]
- Shanghai Municipal Science and Technology Major Project [2018SHZDZX03]
Ask authors/readers for more resources
Myasthenia gravis (MG) is an autoimmune disorder involving T cell-driven, B cell-mediated, and autoantibody-dependent responses against neuromuscular junctions (NMJ). Accumulating evidence suggests the involvement of innate immunity in the pathogenesis of MG, with potential mechanisms related to gene predisposition and viral infection-induced pathways in the Thymus and NMJ immune responses.
Myasthenia gravis (MG) is a T cell-driven, B cell-mediated and autoantibody-dependent autoimmune disorder against neuromuscular junctions (NMJ). Accumulated evidence has emerged regarding the role of innate immunity in the pathogenesis of MG. In this review, we proposed two hypothesis underlying the pathological mechanism. In the context of gene predisposition, on the one hand, Toll-like receptors (TLRs) pathways were initiated by viral infection in the thymus with MG to generate chemokines and pro-inflammatory cytokines such as Type I interferon (IFN), which facilitate the thymus to function as a tertiary lymphoid organ (TLO). On the another hand, the antibodies against acetylcholine receptors (AChR) generated by thymus then activated the classical pathways on thymus and neuromuscular junction (NMJ). Futher, we also highlight the role of innate immune cells in the pathogenic response. Finally, we provide some future perspectives in developing new therapeutic approaches particularly targeting the innate immunity for MG.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available